form8_k11212008.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported) November 20,
2008
Progenics
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-23143
|
|
13-3379479
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
|
777 Old Saw Mill River
Road, Tarrytown, New York
|
|
10591
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant's telephone number,
including area code (914)
789-2800
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(b) On
November 20, 2008, Paul F. Jacobson resigned as a Director of the
Company and Co-Chairman of the Board of Directors in order to focus his
efforts on a new business venture. In conveying his resignation, Mr.
Jacobson said, “It has been a pleasure working with Progenics all these years,
and gratifying to be a part of its accomplishments. I wish the
company and its people all my best for continued success.”
Paul J.
Maddon, M.D., Ph.D., Chief Executive Officer, Chief Science Officer and Founder
of the Company, said, “Paul Jacobson has made many significant contributions to
Progenics during his 18 years of service on our Board. We wish him well in his
future endeavors.”
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
PROGENICS
PHARMACEUTICALS, INC.
By: /s/ ROBERT A.
MCKINNEY
Robert A.
McKinney
Chief Financial Officer, Senior
Vice President,
Finance & Operations and
Treasurer
Date: November 21,
2008